IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S.

Edwards Lifesciences recently announced it would report its first-quarter 2026 results on April 23, with early commentary ...

Edwards Lifesciences has claimed the FDA’s first approval of a transcatheter replacement implant for a leaky tricuspid heart valve, three months after garnering a green light in Europe. The Evoque, ...

IRVINE, Calif. - Edwards Lifesciences Corporation (NYSE: NYSE:EW) today gained the U.S. Food and Drug Administration (FDA) approval for its EVOQUE tricuspid valve replacement system, a ...

While minimally invasive repair devices have shown progress in stemming leaks of the heart’s notoriously tricky tricuspid valve, Edwards Lifesciences aims to show that replacing the valve entirely ...

Just a smidge over 16 years ago, Edwards Lifesciences made heart valve history when it brought the first transcatheter aortic valve replacement (TAVR) system to market in Europe. Now, the TAVR pioneer ...